Rockwell Med (RMTI) AI Stock Analysis

1 Followers

Rockwell Med

(BX Swiss:RMTI)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Sales and customer expansionStrong quarterly sales growth, supported by both new customers and increased purchasing from major dialysis providers, indicates improving commercial traction. Broader customer adoption can strengthen recurring demand, improve operating leverage, and support the company’s competitive position over the next several quarters.

Negative Factors

Persistent unprofitabilityOngoing operating and net losses show that revenue growth has not yet translated into sustainable earnings. Negative returns on equity and low gross margins limit internal funding capacity, reduce the cushion for execution challenges, and make profitability improvement essential to long-term value creation.

Rockwell Med Business Overview & Revenue Model

Company Description

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron...

Rockwell Med Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|Next Earnings Date:May 17, 2021

Earnings Call SentimentPositive

The call was strongly optimistic about core hemodialysis sales growth, improved gross profit and margins, customer expansion, the potential scale of the pending Vantage acquisition, and the supportive direction of the HHS Kidney Care National Plan. However, the company reported operating losses, negative adjusted EBITDA, higher input and freight costs, a lower cash balance and withdrawal of full-year guidance. Overall, the positive operating momentum and strategic acquisition opportunity significantly outweighed the disclosed financial challenges.

Positive Updates

Third-Quarter Net Sales Growth

Third-quarter 2026 net sales were $19.1 million, representing a 20% increase over the same period in 2025. The increase was primarily driven by sales to new customers in the West and larger purchasing volumes from existing customers, particularly the top 5 dialysis providers in the U.S.

Negative Updates

Higher Freight, Material and Supply Costs

Third-quarter gross margin was negatively impacted by higher freight, material and supply costs, which were driven in part by increased diesel costs. Rockwell stated that it is optimizing its supply chain to mitigate these cost pressures.

Company Guidance

Rockwell Medical withdrew all full year 2020 guidance, including net sales, gross margin, adjusted EBITDA, operating cash, and operating cash flow, in consideration of the pending Vantage HD business acquisition and related expenses incurred during the third quarter and related expenses expected to be incurred during the fourth quarter of 2026; the Vantage transaction is currently expected to close in mid-2027, and the combined business is expected to generate annual revenue between $400 million and $450 million, approximately 90% of which is expected to be recurring, with a global workforce of more than 1000 employees across more than 36 countries; Rockwell expects to work alongside Vantage over the next 6 to 9 months until it is able close the transaction and expects to give guidance for the full company sometime in March after the 10-K is released and the end of year announcement, typically the same sort of guidance it has been giving.

Rockwell Med Risk Analysis

Rockwell Med disclosed 35 risk factors in its most recent earnings report. Rockwell Med reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Rockwell Med Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:RMTI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ETON	82Outperform	$1.95B	38.75	104.82%	―	100.61%	―
ANIP	72Outperform	$1.64B	13.72	20.00%	―	25.94%	203.25%
PCRX	66Neutral	$1.46B	38.29	5.53%	―	3.70%	101.62%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	49Neutral	$79.41M	1.33	202.58%	22.65%	-39.11%	-241.27%
ORGO	39Underperform	$121.39M	-0.89	-46.25%	―	-24.33%	-1171.44%

* Healthcare Sector Average

Performance Comparison

CH:RMTI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
PCRX	Pacira	36.46	12.84	54.36%
ANIP	Ani Pharmaceuticals	71.09	-13.46	-15.92%
CPIX	Cumberland Pharmaceuticals Inc.	6.12	4.50	277.78%
ORGO	Organogenesis Holdings	1.05	-5.16	-83.09%
ETON	Eton Pharmaceuticals	68.40	51.52	305.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Rockwell Med AI Stock Analysis